Drug reference

Temoporfin

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1038

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Drug Action

Temoporﬁn accumulates in malignant tissue and is activated by laser light to produce a cytotoxic effect.

PDF page 1038

Indications And Dose

Photodynamic therapy of advanced head and neck squamous cell carcinoma refractory to, or unsuitable for, other treatments ▶BY SLOW INTRAVENOUS INJECTION ▶Adult: (consult product literature)

PDF page 1038

Contra Indications

Acute porphyrias p. 1120. concomitant photosensitising treatment. diseases exacerbated by light. elective surgery. ophthalmic slit- lamp examination for 30 days after administration

PDF page 1038

Safety

Side Effects

▶Common or very common Anaemia. constipation. dizziness. dysphagia. fever. haemorrhage. headache. local infection. nausea. oedema. oral disorders. pain. paraesthesia. photosensitivity reaction (sunscreens ineffective). skin reactions. stomatitis necrotising. sunburn. vomiting ▶Frequency not known Fistula. obstructive airway disorder. sepsis. vascular rupture

PDF page 1038

Conception And Contraception

Manufacturer advises avoid pregnancy for at least 3 months after treatment.

PDF page 1038

Pregnancy

Toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 1038

Breast Feeding

Manufacturer advises avoid breastfeeding for at least 1 month after treatment—no information available.

PDF page 1038

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Solution for injection ▶Foscan (Biolitec Pharma Ltd) Temoporfin 1 mg per 1 ml Foscan 3mg/3ml solution for injection vials | 1 vial P £1,800.00 (Hospital only) Foscan 6mg/6ml solution for injection vials | 1 vial P £3,400.00 (Hospital only) Targeted therapy responsive malignancy ANTINEOPLASTIC DRUGS › PROTEASOME INHIBITORS

PDF page 1038

Clinical care

Patient And Carer Advice

Photosensitivity Avoid exposure of skin and eyes to direct sunlight or bright indoor light for at least 15 days after administration. Avoid prolonged exposure of injection site arm to direct sunlight for 6 months after administration. If extravasation occurs protect area from light for at least 3 months.

PDF page 1038

Dose text by age group

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1038

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Temoporfin

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1038

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Drug Action

Temoporﬁn accumulates in malignant tissue and is activated by laser light to produce a cytotoxic effect.

PDF page 1038

Indications And Dose

Photodynamic therapy of advanced head and neck squamous cell carcinoma refractory to, or unsuitable for, other treatments ▶BY SLOW INTRAVENOUS INJECTION ▶Adult: (consult product literature)

PDF page 1038

Contra Indications

Acute porphyrias p. 1120. concomitant photosensitising treatment. diseases exacerbated by light. elective surgery. ophthalmic slit- lamp examination for 30 days after administration

PDF page 1038

Safety

Side Effects

PDF page 1038

Conception And Contraception

Manufacturer advises avoid pregnancy for at least 3 months after treatment.

PDF page 1038

Pregnancy

Toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 1038

Breast Feeding

Manufacturer advises avoid breastfeeding for at least 1 month after treatment—no information available.

PDF page 1038

Dose and formulations

Medicinal Forms

PDF page 1038

Clinical care

Patient And Carer Advice

PDF page 1038

Dose text by age group

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1038

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.